Skip to Content
Global News Select

Aerie Completes Enrollment of Phase 3 Glaucoma Study in Japan

By Matt Grossman

 

Aerie Pharmaceuticals Inc. has completed patient enrollment of a Phase 3 study in Japan testing its netarsudil ophthalmic solution as a treatment for glaucoma or ocular hypertension, Aerie said Thursday.

The Durham, N.C.-based pharmaceutical company said that the study has enrolled 245 patients. The patients have received treatment either with netarsudil or with ripasudil, another solution that is approved in Japan. The trial is expected to be completed by the end of 2021, Aerie said.

Netarsudil has already been approved to treat some eye conditions in the U.S. The Japanese study is being co-funded with Santen Pharmaceutical Co., which has an exclusive collaboration and license agreement with Aerie for netarsudil in Japan and other Asian countries.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

June 17, 2021 06:55 ET (10:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.